Fosamax and Osteonecrosis of the Jaw: Legal Considerations for New York Patients

From General Health Awareness to Targeted Risk Assessment

For decades, general health and science communication has served as the foundation for public understanding of medication risks and benefits. This legacy framework emphasizes broad awareness of therapeutic options, side effect profiles, and the importance of informed patient-provider dialogue. Within this context, bisphosphonate therapies like Fosamax were widely discussed for their role in managing osteoporosis, with attention focused on skeletal benefits and common gastrointestinal tolerability issues. As public health discourse matured, a more granular concern emerged: the potential for prolonged bisphosphonate exposure to be associated with atypical bone conditions, particularly in the jaw. This shifted the conversation from general medication literacy to a more targeted occupational and patient safety perspective. For individuals who have taken Fosamax over extended periods, the question of cumulative exposure risk becomes paramount—especially for those in New York, where legal frameworks around product liability and statutes of limitations require careful navigation.

​

Understanding Fosamax and Its Association with Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline of Exposure and Onset of Symptoms

The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including postmenopausal osteoporosis and bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research underscores the complex biological mechanisms linking Fosamax to ONJ, though the precise mechanistic pathways remain under investigation.

Statute of Limitations for Fosamax Claims in New York

Regarding settlement-related considerations for affected patients in New York, the statute of limitations is a critical factor. The statute of limitations for personal injury claims, including those related to Fosamax and ONJ, generally requires that a lawsuit be filed within a certain period from the date the injury was discovered or should have been discovered. In New York, the statute of limitations for personal injury actions is typically three years from the date of injury. However, for claims involving medical products like Fosamax, the timeline may be influenced by when the patient became aware of the link between the drug and ONJ. Given that ONJ can develop months to years after starting Fosamax, and that symptoms may not be immediately recognized as drug-related, the discovery rule may apply, extending the filing deadline. Patients should consult with a legal professional to determine their specific filing window.

Adequacy of Warnings and Risk Context

The adequacy of warnings regarding Fosamax and ONJ is a key risk anchor. The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the warning also states that in placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This may raise questions about whether the warning was sufficiently clear about the risk, particularly for patients who developed ONJ after prolonged use. The timeline between exposure to Fosamax and documented harm is variable. ONJ can occur spontaneously or after dental procedures, and the time to onset of symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients considering a settlement, documenting the timing of Fosamax use, dental procedures, and onset of ONJ symptoms is essential.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Provide your details below to see if you qualify.

Do not fill

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.

By clicking the button below, I expressly consent to be contacted by the operator of this website and one legal intake partner matched to my inquiry via phone calls, emails, and/or text messages at the number provided. I understand that this contact may include the use of an automated telephone dialing system (ATDS) or artificial/prerecorded voices. I acknowledge that my consent is not a condition of purchasing any goods or services, and I can revoke it at any time. Start My Free Case Review

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in New York?

In New York, the statute of limitations for personal injury claims is generally three years from the date of injury. However, for claims involving Fosamax and ONJ, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Fosamax caused their ONJ. Because ONJ can develop months to years after starting Fosamax, patients may have additional time to file. It is crucial to consult an attorney to determine the specific deadline for your case.

What are the known risk factors for developing osteonecrosis of the jaw from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Related Articles

• Does Fosamax cause Osteonecrosis of the Jaw
• Statute of limitations for Fosamax in Massachusetts
• Long term outcome of Osteonecrosis of the Jaw after Fosamax
• Ohio Fosamax Osteonecrosis of the Jaw injury lawyer
• Illinois Fosamax Osteonecrosis of the Jaw injury lawyer

References

1. Fosamax Prescribing Information (DailyMed)
2. Bisphosphonate ONJ Risk Information (DailyMed)
3. Multiscale Characterization of Jawbone (PubMed)

Request a Free Case Review

Begin Assessment

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.